The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment.
Yeon Hee Park
No relevant relationships to disclose
Hyun Ae Jung
No relevant relationships to disclose
Won Jin Chang
No relevant relationships to disclose
Moon Ki Choi
No relevant relationships to disclose
Jung Yong Hong
No relevant relationships to disclose
Oh-Nam Ok
No relevant relationships to disclose
Jeong Ju Seo
No relevant relationships to disclose
Yoon-La Choi
No relevant relationships to disclose
Ingu Do
No relevant relationships to disclose
Jin Seok Ahn
No relevant relationships to disclose
Young-Hyuck Im
No relevant relationships to disclose